Jan. 5, 2024 — Eli Lilly, maker of the anti-obesity drug Zepbound, introduced this week the launch of LillyDirect, a direct-to-patient portal, permitting some sufferers to acquire its drug for as little as $25 a month.

The transfer is seen as a serious shift in the way in which these standard drugs can attain sufferers. 

For most of the 42 million People with weight problems, weight reduction drugs resembling Wegovy, Saxenda, and the brand-new Zepbound could be a godsend, serving to them lose the surplus kilos they’ve struggled with for many years or a lifetime.

However getting these drugs has been a battle for a lot of who’re eligible. Shortages of the medicine have been one barrier, and prices of as much as $1,300 month-to-month – the value tag with out insurance coverage protection – are one other hurdle.

However 2024 could also be a a lot brighter 12 months, because of Lilly’s new portal in addition to different developments:

  • Insurance coverage protection on non-public well being plans, whereas nonetheless spotty, could also be enhancing. Federal legislators are combating a 2003 regulation that forbids Medicare from paying for the drugs when prescribed for weight problems.
  • New analysis discovered that semaglutide (Wegovy) can scale back the danger of recurrent strokes and coronary heart assaults in addition to deaths from cardiovascular occasions in these with weight problems and preexisting heart problems (or ailments of the guts and blood vessels), a discovering specialists mentioned ought to get the eye of well being insurers.

The drugs, additionally known as GLP-1 agonists, work by activating the receptors of hormones (known as glucagon-like peptide 1 and others) which might be naturally launched after consuming. That, in flip, makes you’re feeling extra full, resulting in weight lack of as much as 22% for some. The drugs are authorized for these with a physique mass index (BMI) of 30 or a BMI of 27 with at the very least one different weight-related well being situation resembling hypertension or excessive ldl cholesterol. The medicines, injected weekly or extra usually, are prescribed together with recommendation a couple of reduced-calorie food regimen and elevated bodily exercise.


Eli Lilly launched its direct-to-patient portal on Thursday, offering its weight problems medication (in addition to diabetes and migraine medicine) direct to the buyer. Sufferers can entry the weight problems medicines by the telehealth platform FORM. Sufferers attain unbiased telehealth suppliers, in response to Lilly, who can complement a affected person’s present physician or be a substitute for in-patient care in some instances. 

Prices fluctuate, relying on protection, however a 1-month or 3-month provide for somebody with industrial insurance coverage protection might be as little as $25 a month; these with an insurance coverage plan that doesn’t cowl the drug may pay $550 for a one-month provide, in response to Lilly.


Eli Lilly officers didn’t reply to requests for remark. 

Some weight problems specialists welcomed the brand new service. “Any program that improves availability and affordability of those ground-breaking drugs is welcome information for our long-suffering sufferers,” mentioned Louis Aronne, MD, director of the Complete Weight Management Middle at Weill Cornell Medication in New York Metropolis, a long-time weight problems researcher.

“It’s an incredible transfer for Lilly to do,” agreed Caroline Apovian, MD, a professor of drugs at Harvard Medical College and co-director of the Middle for Weight Administration and Wellness at Brigham & Ladies’s Hospital in Boston, who can also be a veteran weight problems specialist. “It’s attempting to assist the accessibility situation and do it responsibly.” 

“The underside line is, there’s an amazing quantity of client want and want for these drugs and never sufficient channels [to provide them],” mentioned Zeev Neuwirth, MD, a former govt at Atrium Well being who writes about well being care traits. “Eli Lilly is responding to a market want that’s on the market and fairly truthfully persevering with to develop.” 

There are nonetheless issues and questions, Neuwirth mentioned, “particularly since that is to my data the primary of its sort when it comes to a pharmaceutical producer instantly meting out remedy on this nontraditional approach.”

He known as for transparency between telehealth suppliers and the pharmaceutical firm to rule out any conflicts of curiosity. 

The American Faculty of Physicians, a company of inside medication docs and others, issued a press release expressing concern. Omar T. Atiq, MD, group’s president, mentioned his group is “involved by the event of internet sites that allow sufferers to order prescription drugs instantly from the drugmakers. Whereas info on in-person care is obtainable, this direct-to-consumer method is primarily oriented round using telehealth providers to prescribe a drug maker’s merchandise.”

The group urged that a longtime patient-doctor relationship be current, or that care ought to occur in session with a health care provider who does have a longtime relationship (the latter an possibility provided by Lilly). “These direct-to-consumer providers have the potential to go away sufferers confused and misinformed about drugs.”

Coronary heart Assault, Stroke Discount Advantages

Earlier analysis has discovered that the GLP-1 medicines resembling Ozempic (semaglutide), which the FDA authorized to deal with diabetes, additionally scale back the danger of cardiovascular points resembling strokes and coronary heart assaults. Now, new analysis finds that semaglutide on the Wegovy dose (normally barely larger than the Ozempic dose for diabetes) additionally has these advantages in those that don’t have a diabetes prognosis however do have weight problems and heart problems.

In a scientific trial sponsored by Novo Nordisk, the maker of Wegovy, half of greater than 17,000 folks with weight problems got semaglutide (Wegovy); the opposite half received a placebo. In comparison with these on the placebo, those that took the Wegovy had a 20% discount in strokes, coronary heart assaults, and deaths from cardiovascular causes over a 33-month interval. 

The examine outcomes are a “massive deal,” Aronne mentioned. The outcomes make it clear that these with weight problems however not diabetes will get the cardiovascular advantages from the therapy as properly. Whereas extra evaluation is critical, he mentioned the essential level is that the examine confirmed that lowering physique weight is linked to enchancment in essential well being outcomes.

Because the analysis evolves, he mentioned, it’s going to be tough for insurers to disclaim drugs within the face of these findings, which promise reductions in long-term well being care prices.

Insurance coverage Protection

In November, the American Medical Affiliation voted to undertake a coverage to induce insurance coverage protection for evidence-based therapy for weight problems, together with the brand new weight problems drugs.

“No single group goes to have the ability to persuade insurers and employers to cowl this,” Aronne mentioned. “However I believe a outstanding group just like the AMA including their voice to the rising refrain goes to assist.”

Protection of GLP-1 drugs may practically double in 2024, in response to a survey of 500 human sources decision-makers launched in October by Accolade, a customized well being care advocacy and supply firm. Whereas 25% of respondents mentioned they at the moment provided protection when the survey was accomplished in August and September, 43% mentioned they intend to supply protection in 2024.

In an e-mail, David Allen, a spokesperson for America’s Well being Insurance coverage Plans, a well being care trade affiliation, mentioned: “Each American deserves reasonably priced protection and high-quality care, and that features protection and look after evidence-based weight problems remedies and therapies.”

He mentioned “scientific leaders and different specialists at medical insurance suppliers routinely evaluation the proof for all sorts of remedies, together with remedies for weight problems, and supply a number of choices to sufferers – starting from life-style adjustments and diet counseling, to surgical interventions, to prescribed drugs.” 

Allen mentioned the proof that weight problems medicine assist with weight reduction “continues to be evolving.”

“And a few sufferers are experiencing dangerous results associated to those medicine resembling vomiting and nausea, for instance, and the chance of gaining the burden again when discontinuing the medicine,” he mentioned. 

Others are combating for Medicare protection, whereas some specialists contend the prices of that protection could be overwhelming. A bipartisan invoice, the Deal with and Cut back Weight problems Act of 2023, would enable protection below Medicare’s prescription drug profit for medicine used for the therapy of weight problems or for weigh loss administration for people who find themselves obese. Some say it’s an uphill climb, citing a Vanderbilt College evaluation that discovered giving simply 10% of Medicare-eligible sufferers the medicine would price $13.6 billion to greater than $26 billion.

Nevertheless, a white paper from the College of Southern California concluded that the worth to society of masking the medicine for Medicare recipients would equal practically $1 trillion over 10 years, citing financial savings in hospitalizations and different well being care prices.

Complete insurance coverage protection is required, Apovian mentioned. Non-public insurance policy, Medicare, and Medicaid should all notice the significance of masking what has been now proven to be life-saving medicine, she mentioned. 

Broader protection may also scale back the variety of sufferers getting weight problems medicine from unreliable sources, in an effort to save cash, and having adversarial results. The FDA warned towards counterfeit semaglutide in December.

Lengthy-Time period Image

Analysis suggests the weight problems drugs should be taken constantly, at the very least for most individuals, to keep up the burden loss. In a examine of sufferers on Zepbound, Aronne and colleagues discovered that withdrawing the remedy led folks to regain weight, whereas persevering with it led to sustaining and even rising the preliminary weight reduction. Whereas some might be able to use the drugs solely every so often, “the bulk should take these on a continual foundation,” Aronne mentioned.

Weight problems, like hypertension and different continual situations, wants steady therapy, Apovian mentioned. Nobody would counsel withdrawing blood strain drugs that stabilize blood strain; the identical must be true for the weight problems medicine, she mentioned.

Apovian consults for FORM, the telehealth platform Lilly makes use of for LillyDirect, and consults for Novo Nordisk, which makes Saxenda and Wegovy. Aronne is a guide and investigator for Novo Nordisk, Eli Lilly, and different corporations.

Supply hyperlink